PUBLISHER: Grand View Research | PRODUCT CODE: 1790242
PUBLISHER: Grand View Research | PRODUCT CODE: 1790242
U.S. Tremfya Market Size, Share & Trends Analysis Report By Application (Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis ), By Distribution Channel, And Segment Forecasts, 2025 - 2033
U.S. Tremfya Market Size & Trends:
The U.S. Tremfya market size was estimated at USD 3.00 billion in 2024 and is projected to reach USD 4.89 billion by 2033, growing at a CAGR of 5.32% from 2025 to 2033. The rising incidence of chronic plaque psoriasis and psoriatic arthritis in the U.S. is contributing to increased demand for advanced biologic treatments. As these autoimmune disorders become more widespread, there is a growing emphasis on therapies that offer lasting disease control and improved patient outcomes. Tremfya (guselkumab), an IL-23 inhibitor, has demonstrated reliable effectiveness in managing moderate-to-severe forms of these conditions.
Its ability to provide sustained symptom relief, combined with a well-tolerated safety profile, has supported its broader adoption. U.S. healthcare professionals, including dermatologists and rheumatologists, are increasingly incorporating Tremfya into treatment regimens. This trend reflects a shift toward precision-targeted biologics that align with long-term management goals.
Tremfya's commercial growth in the U.S. is strongly supported by Janssen Pharmaceuticals' effective marketing efforts and robust competitive strategy. The therapy has carved out a distinct position in the biologics market by demonstrating higher efficacy than several established treatments, such as TNF and IL-17 inhibitors. Clinical comparisons have highlighted its ability to deliver faster skin clearance and maintain results over time. For instance, in October 2024, Johnson & Johnson's SPECTREM study showed Tremfya effectively cleared difficult psoriasis areas like the scalp, face, hands, feet, and genitals, with clearance rates up to 80%. Most patients maintained clear or almost clear skin through week 48. The treatment also significantly improved patients' quality of life by reducing symptoms like itch and pain.
The future growth of the Tremfya market in the U.S. is supported by ongoing clinical development and lifecycle management strategies. Current trials are assessing its use in additional indications such as Crohn's disease and hidradenitis suppurativa, potentially expanding its treatment range. The manufacturer is also conducting real-world evidence research to confirm its effectiveness across varied patient groups. Rising interest in personalized medicine and biomarker-focused treatments is boosting demand for IL-23 inhibitors. Collaborations with specialty pharmacies and efficient distribution systems improve access in key regions. Continued investment in physician training and patient support initiatives strengthens brand engagement.
U.S. Tremfya Market Report Segmentation
This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Tremfya market report based on application and distribution channel:
- Application Outlook (Revenue, USD Billion, 2021 - 2033)
- Plaque Psoriasis
- Psoriatic Arthritis (PsA)
- Others
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Tremfya Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. U.S. Tremfya Market: Application Business Analysis
- 4.1. Application Market Share, 2024 & 2033
- 4.2. Application Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Billion)
- 4.4. Plaque Psoriasis
- 4.4.1. Plaque Psoriasis Market, 2021 - 2033 (USD Billion)
- 4.5. Psoriatic Arthritis (PsA)
- 4.5.1. Psoriatic Arthritis (PsA) Market, 2021 - 2033 (USD Billion)
- 4.6. Others
- 4.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. U.S. Tremfya Market: Distribution Channel Business Analysis
- 5.1. Distribution Channel Market Share, 2024 & 2033
- 5.2. Distribution Channel Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
- 5.4. Hospital Pharmacies
- 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
- 5.5. Retail Pharmacies
- 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
- 5.6. Online Pharmacies
- 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)
Chapter 6. Competitive Landscape
- 6.1. Participant Overview
- 6.2. Company Market Position Analysis
- 6.3. Company Categorization
- 6.4. Strategy Mapping
- 6.5. Company Profiles/Listing
- 6.5.1. Johnson & Johnson Services, Inc.
- 6.5.1.1. Overview
- 6.5.1.2. Financial Performance
- 6.5.1.3. Application Benchmarking
- 6.5.1.4. Strategic Initiatives
- 6.5.1. Johnson & Johnson Services, Inc.
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 U.S. Tremfya market, by application, 2021 - 2033 (USD Billion)
- Table 4.U.S. Tremfya market, by distribution channel, 2021 - 2033 (USD Billion)
List of Figures
- Fig. 1 U.S. Tremfya market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Therapeutic approach and application outlook (USD Billion)
- Fig. 10 Competitive landscape
- Fig. 11 U.S. Tremfya market dynamics
- Fig. 12 U.S. Tremfya market: Porter's five forces analysis
- Fig. 13 U.S. Tremfya market: PESTLE analysis
- Fig. 14 Application market, 2021 - 2033 (USD Billion)
- Fig. 15 Plaque psoriasis market, 2021 - 2033 (USD Billion)
- Fig. 16 Psoriatic Arthritis (PsA) market, 2021 - 2033 (USD Billion)
- Fig. 17 Others market, 2021 - 2033 (USD Billion)
- Fig. 18 Distribution Channel market, 2021 - 2033 (USD Billion)
- Fig. 19 Hospital pharmacies market, 2021 - 2033 (USD Billion)
- Fig. 20 Retail pharmacies market, 2021 - 2033 (USD Billion)
- Fig. 21 Online pharmacies market, 2021 - 2033 (USD Billion)
- Fig. 22 U.S. Tremfya market revenue, by region
- Fig. 23 Country marketplace: Key takeaways
- Fig. 24 U.S. country dynamics
- Fig. 25 U.S. Tremfya market, 2021 - 2033 (USD Billion)
- Fig. 26 Company categorization
- Fig. 27 Company market position analysis
- Fig. 28 Strategic framework
